Literature DB >> 17610500

Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis.

Hideki Niwa1, Motoko Sasaki, Joji Haratake, Takahiko Kasai, Kazuyoshi Katayanagi, Hiroshi Kurumaya, Shinji Masuda, Hiroshi Minato, You Zen, Akio Uchiyama, Atsuo Miwa, Katsuhiko Saito, Yoshiko Sudo, Yasuni Nakanuma.   

Abstract

AIM: Serum antinuclear antibodies (ANA) are occasionally noted in patients with non-alcoholic steatohepatitis (NASH). We examined the significance of ANA in NASH.
METHODS: We compared clinicopathological features in patients with ANA-positive NASH (n = 35) and ANA-negative NASH (n = 36). Inflammatory cell profiles and the distribution of oxidative stress markers were also examined immunohistochemically.
RESULTS: ANA-positive NASH was significantly associated with female gender (P = 0.005), high degree of portal inflammation (P = 0.039), interface activity (P = 0.036) and hepatocellular ballooning (P = 0.0008). In addition, ANA of high titer (320-fold or more) was significantly associated with the histological grade and stage of NASH (P = 0.02). The degree of steatosis wais rather mild in the high-titer ANA group(P = 0.01). The analysis of inflammatory cell profiles revealed that CD3-positive T cells were predominant and plasma cells were rather few in the portal area and hepatic lobules in both ANA-positive and ANA-negative groups. There was no difference in the distribution of oxidative stress markers between ANA-positive and ANA-negative groups.
CONCLUSION: These findings suggest that the presence of ANA may be related to the progression of NASH and that a different type of autoimmune mechanism may be involved in the pathogenesis of NASH with ANA, compared to the pathogenesis of autoimmune hepatitis.

Entities:  

Year:  2007        PMID: 17610500     DOI: 10.1111/j.1872-034X.2007.00150.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  14 in total

1.  Autoimmune Markers Do Not Impact Clinical Presentation or Natural History of Steatohepatitis-Related Liver Disease.

Authors:  Sujan Ravi; Mohamed Shoreibah; Evan Raff; Joseph Bloomer; Donny Kakati; Khalid Rasheed; Ashwani K Singal
Journal:  Dig Dis Sci       Date:  2015-07-15       Impact factor: 3.199

2.  Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.

Authors:  Raj Vuppalanchi; Robert J Gould; Laura A Wilson; Aynur Unalp-Arida; Oscar W Cummings; Naga Chalasani; Kris V Kowdley
Journal:  Hepatol Int       Date:  2011-05-10       Impact factor: 6.047

3.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

4.  Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan.

Authors:  Yoshio Sumida; Yuichiro Eguchi; Masafumi Ono
Journal:  World J Hepatol       Date:  2010-10-27

5.  Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease.

Authors:  Javier De Luca-Johnson; Kirk J Wangensteen; Joshua Hanson; Edward Krawitt; Rebecca Wilcox
Journal:  Dig Dis Sci       Date:  2016-06-04       Impact factor: 3.199

Review 6.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.

Authors:  Raj Vuppalanchi; Naga Chalasani
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

7.  Significance of autoantibody seropositivity in children with obesity and non-alcoholic fatty liver disease.

Authors:  Toshifumi Yodoshi; Sarah Orkin; Ana Catalina Arce-Clachar; Kristin Bramlage; Stavra A Xanthakos; Marialena Mouzaki; Pamela L Valentino
Journal:  Pediatr Obes       Date:  2020-07-08       Impact factor: 3.910

8.  Verification of B-lymphocyte activating factor's involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease.

Authors:  Takashi Himoto; Koji Fujita; Takako Nomura; Joji Tani; Asahiro Morishita; Hirohito Yoneyama; Reiji Haba; Tsutomu Masaki
Journal:  Diabetol Metab Syndr       Date:  2017-06-13       Impact factor: 3.320

Review 9.  Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation.

Authors:  Elizabeth M Brunt
Journal:  Hepatol Commun       Date:  2017-06-07

10.  The Efficacy of Corticosteroid Therapy in a Patient with Non-alcoholic Steatohepatitis Overlapping Autoimmune Hepatitis.

Authors:  Takuya Komura; Hajime Ohta; Takuya Seike; Yoshiaki Shimizu; Ryotaro Nakai; Hitoshi Omura; Takashi Kagaya; Satomi Kasashima; Atsuhiro Kawashima; Sakae Oba; Kennichi Harada; Shuichi Kaneko; Masashi Unoura
Journal:  Intern Med       Date:  2017-11-20       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.